<unk>  is an antineoplastic agent that is FDA approved for the treatment of adult patients with chronic or accelerated phase chronic myeloid leukemia (CML) with resistance and/or intolerance to two or more tyrosine kinase inhibitors (TKI).   Common adverse reactions include pancytopenia, thrombocytopenia, increased alanine aminotransferase, myelosuppression, bleeding and hyperglycemia.
Omacetaxine
Tapentadol
Crotamiton
Profenamine
Methadone 
Oxydeprofos
Hydrocodone
Doxofylline